Currently Viewing Posts Tagged 上海品茶网ABA

Consumer groups urge Italian and Belgian authorities to investigate Biogen over Spinraza pricing

first_img @Pharmalot Scott LaPierre/Boston Globe Ed Silverman Consumer groups urge Italian and Belgian authorities to investigate Biogen over Spinraza pricing Log In | Learn More Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+. First 30 days free. GET STARTED About the Author Reprints What is it? Pharmalot Columnist, Senior Writer Ed covers the pharmaceutical industry. Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day STAT+ Conversations Weekly opportunities to engage with our reporters and leading industry experts in live video conversations Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.center_img A pair of consumer advocacy groups wants antitrust authorities in Italy and Belgium to investigate Biogen (BIIB) for allegedly abusing its “position in the marketplace” by imposing an “unfair price” for Spinraza, a pricey therapy for treating a rare and fatal childhood disease called spinal muscular atrophy.In arguing their case, the advocacy groups maintain that there is an “excessive” and “disproportionate” difference between the development costs for the medicine and what the Italian and Belgian health systems are paying. And they want authorities to take action in order to strike a balance between innovation and access. STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond. What’s included? Tags Bostondrug pricinglegalpharmaceuticalsrare diseasesSTAT+ Pharmalot GET STARTED By Ed Silverman July 25, 2019 Reprints [email protected] last_img read more